Effectiveness of Antiseizure Medication Duotherapies in Patients With Glioma

Background and Objectives About 30% of patients with glioma need an add-on antiseizure medication (ASM) due to uncontrolled seizures on ASM monotherapy. This study aimed to determine whether levetiracetam combined with valproic acid (LEV + VPA), a commonly prescribed duotherapy, is more effective than other duotherapy combinations including either LEV or VPA in patients with glioma. Methods In this multicenter retrospective observational cohort study, treatment failure (i.e., replacement by, addition of, or withdrawal of an ASM) for any reason was the primary outcome. Secondary outcomes included (1) treatment failure due to uncontrolled seizures and (2) treatment failure due to adverse effects. Time to treatment failure was estimated from the moment of ASM duotherapy initiation. Multivariable cause-specific Cox proportional hazard models were estimated to study the association between risk factors and treatment failure. The maximum duration of follow-up was 36 months. Results A total of 1,435 patients were treated with first-line monotherapy LEV or VPA, of which 355 patients received ASM duotherapy after they had treatment failure due to uncontrolled seizures on monotherapy. LEV + VPA was prescribed in 66% (236/355) and other ASM duotherapy combinations including LEV or VPA in 34% (119/355) of patients. Patients using other duotherapy vs LEV + VPA had a higher risk of treatment failure for any reason (cause-specific adjusted hazard ratio [aHR] 1.50 [95% CI 1.07–2.12], p = 0.020), due to uncontrolled seizures (cause-specific aHR 1.73 [95% CI 1.10–2.73], p = 0.018), but not due to adverse effects (cause-specific aHR 0.88 [95% CI 0.47–1.67], p = 0.703). Discussion This observational cohort study suggests that LEV + VPA has better efficacy than other ASM combinations. Similar toxicities were experienced in the 2 groups. Classification of Evidence This study provides Class III evidence that for patients with glioma with uncontrolled seizures on ASM monotherapy, LEV + VPA has better efficacy than other ASM combinations.

[1]  M. J. van den Bent,et al.  Prescription preferences of antiepileptic drugs in brain tumor patients: An international survey among EANO members , 2021, Neuro-oncology practice.

[2]  M. J. van den Bent,et al.  First‐line antiepileptic drug treatment in glioma patients with epilepsy: Levetiracetam vs valproic acid , 2021, Epilepsia.

[3]  M. Taphoorn,et al.  Retention rates of antiepileptic drugs in glioma patients: the most appropriate outcome , 2020, CNS oncology.

[4]  J. Reijneveld,et al.  Effectiveness and tolerability of lacosamide as add‐on therapy in patients with brain tumor–related epilepsy: Results from a prospective, noninterventional study in European clinical practice (VIBES) , 2020, Epilepsia.

[5]  P. Kwan,et al.  Tolerability of Antiseizure Medications in Individuals With Newly Diagnosed Epilepsy. , 2020, JAMA neurology.

[6]  Versione,et al.  Common Terminology Criteria for Adverse Events , 2020, Definitions.

[7]  Mark Payne,et al.  Health and Human Services , 2020, Congress and the Nation 2013-2016, Volume XIV: Politics and Policy in the 113th and 114th Congresses.

[8]  P. Wen,et al.  Use of the Response Assessment in Neuro-Oncology (RANO) criteria in clinical trials and clinical practice , 2019, CNS oncology.

[9]  S. Shete,et al.  Glioma-related seizures in relation to histopathological subtypes: a report from the glioma international case–control study , 2018, Journal of Neurology.

[10]  Patrick Kwan,et al.  Treatment Outcomes in Patients With Newly Diagnosed Epilepsy Treated With Established and New Antiepileptic Drugs: A 30-Year Longitudinal Cohort Study , 2017, JAMA neurology.

[11]  K. Phan,et al.  Association Between IDH1 and IDH2 Mutations and Preoperative Seizures in Patients with Low-Grade Versus High-Grade Glioma: A Systematic Review and Meta-Analysis. , 2017, World neurosurgery.

[12]  G. Avanzini,et al.  Patterns of care of brain tumor-related epilepsy. A cohort study done in Italian Epilepsy Center , 2017, PloS one.

[13]  Chava L. Ramspek,et al.  Prediction versus aetiology: common pitfalls and how to avoid them: Clinical Epidemiology in Nephrology , 2017, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[14]  Y. Gupta,et al.  Adverse effects & drug load of antiepileptic drugs in patients with epilepsy: Monotherapy versus polytherapy , 2017, The Indian journal of medical research.

[15]  M. T. Herdeiro,et al.  Imputation of adverse drug reactions: Causality assessment in hospitals , 2017, PloS one.

[16]  G. Reifenberger,et al.  The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary , 2016, Acta Neuropathologica.

[17]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .

[18]  E. Perucca.  Optimizing antiepileptic drug treatment in tumoral epilepsy , 2013, Epilepsia.

[19]  A. Matagne,et al.  Synergism of lacosamide with established antiepileptic drugs in the 6‐Hz seizure model in mice , 2013, Epilepsia.

[20]  M. Taphoorn,et al.  Effect of valproic acid on seizure control and on survival in patients with glioblastoma multiforme. , 2013, Neuro-oncology.

[21]  B. Bourgeois,et al.  Updated ILAE evidence review of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes , 2013, Epilepsia.

[22]  T. Jiang,et al.  Seizure characteristics and outcomes in 508 Chinese adult patients undergoing primary resection of low-grade gliomas: a clinicopathological study. , 2012, Neuro-oncology.

[23]  M. Brodie,et al.  Combining antiepileptic drugs—Rational polytherapy? , 2011, Seizure.

[24]  E. S. St. Louis.  Truly “Rational” Polytherapy: Maximizing Efficacy and Minimizing Drug Interactions, Drug Load, and Adverse Effects , 2009, Current neuropharmacology.

[25]  E. S. Louis.  Truly "rational" polytherapy: maximizing efficacy and minimizing drug interactions, drug load, and adverse effects. , 2009 .

[26]  M. Taphoorn,et al.  Efficacy of anti-epileptic drugs in patients with gliomas and seizures , 2009, Journal of Neurology.

[27]  P. Patsalos,et al.  Benefit of combination therapy in epilepsy: A review of the preclinical evidence with levetiracetam , 2009, Epilepsia.

[28]  R. Sachdeo.  The evidence-based rationale for monotherapy in appropriate patients with epilepsy , 2007, Neurology.

[29]  H Putter,et al.  Tutorial in biostatistics: competing risks and multi‐state models , 2007, Statistics in medicine.

[30]  R. Raedt,et al.  Levetiracetam: the profile of a novel anticonvulsant drug-part I: preclinical data. , 2007, CNS drug reviews.

[31]  Tracy Glauser,et al.  ILAE Treatment Guidelines: Evidence‐based Analysis of Antiepileptic Drug Efficacy and Effectiveness as Initial Monotherapy for Epileptic Seizures and Syndromes , 2006, Epilepsia.

[32]  K. Nocka,et al.  The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[33]  W. Löscher.  Basic pharmacology of valproate: a review after 35 years of clinical use for the treatment of epilepsy. , 2002, CNS drugs.

[34]  R. Gray.  A Class of $K$-Sample Tests for Comparing the Cumulative Incidence of a Competing Risk , 1988 .

[35]  E. Perucca,et al.  Interaction between phenytoin and valproic acid: Plasma protein binding and metabolic effects , 1980, Clinical pharmacology and therapeutics.